Breast cancer in elderly patients: a clinicopathological review of a Nigerian database

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia

Opinion: Premature regulatory approval by the FDA

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma